Invivyd shares closed up about 5% to roughly $0.72, a rare green day after a weak three month run. Yet the headline story sits on the income statement. The latest trailing twelve month figures still show heavy losses, with net income from continuing operations firmly in the red and basic earnings per share negative. That gap between a flicker of optimism in the price and the ongoing loss profile sets up a clear tension for investors.

The key question now is whether the market is rewarding the growth pipeline too quickly while the company continues to burn cash at scale.

Is Invivyd at US$0.72 a deep discount to its estimated US$43.33 fair value, or a signal that losses and dilution still weigh heavily on the story? See how the valuation case stacks up in our valuation analysis for Invivyd.

Q2 2026 Earnings Summary

• Total Revenue, TTM vs. TTM PCP: US$55.87m vs. US$36.69m (change reflects higher trailing twelve month revenue compared with the prior period)
• Net Loss from Continuing Operations, TTM vs. TTM PCP: loss of US$77.60m vs. loss of US$142.72m (decline in reported losses over the trailing twelve months)
• Basic EPS, TTM vs. TTM PCP: loss of US$0.35 per share vs. loss of US$1.19 per share (loss per share narrowed on a trailing twelve month basis)
• Pipeline Progress, Current vs. PCP: 1 product in Phase III and 2 products in Phase I vs. no disclosed Phase I or Phase III products in the earlier trailing period (pipeline shows more disclosed late stage and early stage programs in the current period)

Prefer clean charts to staring at another wall of numbers? View Invivyd's full valuation picture at a glance in our company report for Invivyd.

Invivyd bull case hinges on pipeline execution

Bulls argue Invivyd can pivot from PEMGARDA dependence to a broader infectious disease franchise supported by a more disciplined cost base. The numbers offer some support. Trailing revenue of US$55.87m sits against a loss from continuing operations of US$77.60m, which is lower than the loss of US$142.72m in the prior comparable period. Loss per share also narrowed from US$1.19 to US$0.35. That lines up with the narrative of tighter expense control while commercial revenue builds. Pipeline breadth has clearly moved forward, with 1 product now in Phase III and 2 in Phase I compared with no disclosed Phase I or Phase III assets previously. For a thesis built on Phase 3 readouts for VYD2311 and early work in RSV and measles, those pipeline milestones have been hit on time, even as earnings remain negative.

Bear case focuses on PEMGARDA risk and dilution

Bears worry that Invivyd is tied to a single COVID antibody and will face ongoing losses and dilution. The 12 month FDA notice to terminate PEMGARDA’s EUA from June 29, 2027 squarely supports that concern. The core commercial product now has a visible regulatory sunset, even as the company is still reporting a trailing loss of US$77.60m. Recent stock performance also reflects pressure. The share price is up 5.09% on the day to about US$0.72, yet it is down about 3% over 7 days, 12% over 30 days and 40% over 90 days. New equity grants to 14 hires underline that stock based compensation and potential dilution continue. Against that backdrop, the current loss making profile and product concentration argue that the bearish focus on risk to future cash flows is not yet resolved.

Compare Invivyd’s tighter loss per share, expanded Phase III and Phase I pipeline, and visible PEMGARDA overhang with how the street is framing the risk and reward. See the consensus price target analysis for Invivyd to check where analyst targets sit against today’s US$0.72 share price.

Stay Ahead With Simply Wall St

If Invivyd’s mix of a US$0.72 share price, widened pipeline and ongoing losses has your attention, register free with Simply Wall St and add it to a Watchlist to watch how price moves against fair value and earnings progress. After you take a position, use the Portfolio Command Center to keep your holdings organised and cut through market noise so only the most important updates reach you. For a longer term view, tap into the Community to see how other investors are thinking about Invivyd and similar stocks. That combination may help you identify potential catalysts and risks early and stay a step ahead of the market.

Seeking Alternatives Beyond Invivyd?

Fresh opportunities can move from quiet to flying quickly. Scan these stock ideas before the crowd catches on and the best entry points start dropping out of reach. Review them while they are still available.

• Target resilient compounding potential in companies screened for strong balance sheets and fundamentals with the curated list of solid balance sheet and fundamentals stocks (50 results).
• Consider potential momentum shifts by reviewing hand picked 83 resilient stocks with low risk scores that still aim to keep downside risk tightly controlled while conditions remain under the radar for now.
• Spot income ideas before yields change by using the curated 10 dividend fortresses that focus on businesses built to sustain higher payouts.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.